Given the abnormal expression of CYSLTR1 and its potential involvement in COVID-19-related inflammation, leukotriene receptor antagonists hold promise as adjunctive therapies for severe COVID-19 patients. This evidence concerns the gene CYSLTR1 and COVID-19.